Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?

Mené sur 34 patients atteints d'un lymphome aggressif à cellules B (âge : 18-80 ans), cet essai de phase I évalue la dose maximale tolérée du vénétoclax en combinaison avec une chimiothérapie de type EPOCH-R à doses ajustées, en traitement de première ligne

Résumé en anglais

Outcomes in patients with diffuse large B-cell lymphoma after first-line immunochemotherapywith rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)are suboptimal, because a third of patients have primary refractory disease or relapsewithin 2 years of therapy. Although salvage treatment with chimeric antigen receptorT-cell therapy has shown promise, this option is unavailable for most patients dueto toxicty, timelines (no time for bridging therapy in cases of rapidly progressivedisease), and economic reasons. Results from studies of other salvage options haveshown modest efficacy at best.